- Oops!Something went wrong.Please try again later.
BALTIMORE, MD / ACCESSWIRE / March 17, 2021 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on Link Reservations, Inc. (OTC PINK:LRSV). The Company is an emerging player in the fast-growing CBD and functional mushrooms markets. This report carries a price target. To view the new research report along with disclosures and disclaimers, or to download them in their entirety, please visit https://bit.ly/3vzHt1t.
Link Reservations Inc is a CBD Pet Care provider dedicated to improving the health and life conditions of pets worldwide. Developing and marketing hemp-based CBD products for cats, dogs and horses, the Company is currently present in Europe and in the US. Link also recently launched a sister site for humans, DailyLifeCBD.com. According to a recent report from Grandview Research, the global Pet CBD market is slated to jump from $27M in 2020 to $400M in 2027, a 40% Compound Annual Growth Rate (CAGR). Meanwhile, Grandview also projects the global CBD market will grow from an estimated $3.5B in 2021 to $13.4B in 2028, a 21% CAGR.
In the Opportunity Research report, analyst Rob Goldman discusses the potential of the Company's Pet CBD and functional mushroom lines and how success in these markets may result in a future premium valuation.
Goldman noted, "Through its two subsidiaries, LRSV is poised to generate a meaningful share in some of the fastest growing wellness markets, namely hemp-based CBD-infused products for pets and humans, and functional mushrooms. The Company offers diverse products in niche, high growth markets and is one of the few CBD products firms to offer products in the US and Europe."
"The projected 40% compound annual growth rate (CAGR) for the Pet CBD market over the next few years illustrates the strong appetite for the offerings. Plus, the unprecedented pet ownership during the pandemic, especially by millennials, fuels this opportunity. CBDs are used to treat anxiety, inflammation, pain, and other conditions. LRSV plans to introduce new mushroom-infused products to treat stress and sleep disorders," continued Goldman.
"The convergence of key markets such as pet care, CBDs, functional mushrooms and potentially psychedelic mushrooms could foster considerable growth, success, and valuation premiums for LRSV. Thus, our target price represents a premium to key CBD-infused product peers," concluded Goldman.
About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, stock market blogs, and popular investment newsletters.
Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
This press release contains excerpts of our most recently published company report on Link Reservations, Inc. The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from Link Reservations, Inc. ("the Company"). The information includes authorized press releases or legal disclosures made in their filings with the U.S. Securities and Exchange Commission http://www.sec.gov.
Separate from the factual content of our report about the Company, we may from time to time include our own opinions about the Company, its business, markets, and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.
A Goldman Small Cap Research report, update, newsletter, article, trading alert, corporate profile, sector or industry snapshot, podcast interview, or press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other regulatory agency. A Speculative Buy rating for our covered companies is defined as a company that we believe exhibits the potential to generate outsized returns despite inherent, above-average business, market, or financial risk. To download this research report or any of our research, view our disclosures and disclaimers, or for more information, visit www.goldmanresearch.com. Goldman Small Cap Research was compensated by a third party in the amount of $3000 for research report production and distribution, including a press release.
Goldman Small Cap Research
Rob Goldman, Analyst
SOURCE: Goldman Small Cap Research
View source version on accesswire.com: